8-K: Genprex Inks Amended License Deal with University of Pittsburgh, Forms Diabetes-Focused Subsidiary

Genprex strengthens its diabetes program with an updated license agreement and the creation of Convergen Biotech, Inc., a wholly-owned subsidiary dedicated to diabetes gene therapy development.

Summary

• Genprex has entered into an amended and restated exclusive license agreement with the University of Pittsburgh (UP) for gene therapy technologies targeting Type 1 and Type 2 diabetes.
• The new agreement consolidates prior licenses into a single agreement, granting Genprex worldwide exclusive rights to certain patents and related technology, and non-exclusive rights to related know-how.
• The licensed technology involves an adeno-associated virus vector containing the Pdx1 and MafA genes, administered directly into the pancreatic duct.
• Genprex is obligated to use its best efforts to bring the licensed technology to market, meeting specific milestones and submitting regular progress reports to UP.
• As consideration, Genprex will pay UP an initial license fee, annual maintenance fees, low single-digit percentage royalties, minimum annual royalties, a low double-digit percentage share of non-royalty sublicense income, and milestone payments up to approximately $4,825,000.
• Genprex has also formed a wholly-owned subsidiary, Convergen Biotech, Inc., to focus on the development of its diabetes program.
• The company anticipates FDA guidance on IND-enabling diabetes studies by the second half of 2025.
• The agreement remains in effect until the later of 20 years after the first commercial sale or the expiration of the last valid patent claim.
• Genprex may terminate the agreement with six months' notice, while UP can terminate for uncured default, failure to meet milestones, or bankruptcy.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Genprex's diabetes program, highlighting the strengthened IP position and strategic focus. However, the inherent risks associated with clinical development and regulatory approvals temper the overall sentiment.

Positives

• The new license agreement strengthens Genprex's intellectual property portfolio in diabetes gene therapy.
• The formation of Convergen Biotech allows for a more focused approach to diabetes program development, potentially attracting direct investment and strategic collaborations.
• The technology has the potential to disrupt the diabetes market by providing long-term efficacy.
• Genprex anticipates FDA guidance on IND-enabling diabetes studies by the second half of 2025.

Negatives

• Genprex is subject to milestone payments and royalties to the University of Pittsburgh, which could impact profitability.
• The success of the diabetes program is dependent on preclinical and clinical trial outcomes, as well as regulatory approvals.
• The termination of the macrophage technology license could limit future development options.

Risks

• Failure to meet milestones outlined in the license agreement could lead to termination of the agreement by the University of Pittsburgh.
• Clinical trials may not be successful, and regulatory approvals may not be granted.
• The company may face challenges in scaling up manufacturing and commercialization of the licensed technology.
• The diabetes market is competitive, and Genprex may face challenges in gaining market share.
• Genprex's ability to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all, is a risk.

Future Outlook

Genprex plans to advance its diabetes gene therapy program, GPX-002, toward human clinical trials and expects FDA guidance on IND-enabling studies by the second half of 2025. The company believes separating its diabetes program into a new subsidiary could expedite clinical development and enable potential direct investment and strategic collaboration.

Management Comments

• 'We are excited about the advances we are making with our diabetes gene therapy program, including the updated, consolidated exclusive license agreement with the University of Pittsburgh for several technology combinations,' said Ryan Confer, President and Chief Executive Officer at Genprex.
• 'We are also pleased to have formed our wholly-owned subsidiary.'
• 'We believe GPX-002 is a highly innovative, emerging diabetes gene therapy, and we are working to advance this program toward human clinical trials.'
• 'The latest exclusive license agreement synergizes our pre-existing relationship with the University of Pittsburgh, strengthens our intellectual property portfolio for the diabetes gene therapy program and provides Genprex with valuable rights over multiple diabetes gene therapy combinations that we believe have the potential to disrupt the diabetes market,' said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing.

Industry Context

The announcement reflects the growing interest in gene therapy as a potential treatment for diabetes, a disease with a significant global prevalence and high healthcare costs. Genprex's focus on both Type 1 and Type 2 diabetes positions it to address a broad market need. The formation of a dedicated subsidiary aligns with a trend of companies streamlining operations to focus on specific therapeutic areas.

Comparison to Industry Standards

• The gene therapy approach of using AAV vectors to deliver Pdx1 and MafA genes to the pancreas is similar to other research efforts in the field of diabetes gene therapy.
• Companies like Vertex Pharmaceuticals are also exploring cell-based therapies for Type 1 diabetes, demonstrating the industry's commitment to finding innovative treatments.
• The milestone payments and royalty rates in the license agreement are within the typical range for biotech licensing deals, but the specific terms are confidential.
• Genprex's plan to seek FDA guidance on IND-enabling studies is a standard regulatory pathway for bringing new gene therapies to market.

Stakeholder Impact

• Shareholders may benefit from the increased focus on the diabetes program and potential for future growth.
• Patients with Type 1 and Type 2 diabetes could potentially benefit from new gene therapy treatments.
• The University of Pittsburgh will receive financial consideration and potential royalties from the license agreement.
• Employees of Genprex and Convergen Biotech will be involved in the development and commercialization of the diabetes program.

Next Steps

• Genprex plans to continue preclinical studies of the licensed technologies.
• The company intends to request FDA guidance for IND-enabling studies.
• Genprex will work to advance the diabetes program toward human clinical trials.
• Convergen Biotech will focus on the development of the diabetes program.

Key Dates

Keywords

Genprex, diabetes, gene therapy, University of Pittsburgh, license agreement, Convergen Biotech, Pdx1, MafA, T1D, T2D, clinical trials, IND, FDA